TNXP
TNXP
NASDAQ · Biotechnology

Tonix Pharmaceuticals Holdin

$14.28
+0.53 (+3.85%)
As of Apr 1, 2:31 PM ET ·
Financial Highlights (FY 2025)
Revenue
84.57M
Net Income
-20,699,385
Gross Margin
59.2%
Profit Margin
-24.5%
Rev Growth
+3.2%
D/E Ratio
0.58
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 59.2% 59.2% 59.2%
Operating Margin -23.9% -24.9% -24.3%
Profit Margin -24.5% -29.4% -31.2%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 84.57M 86.26M 76.53M
Gross Profit 50.02M 51.02M 45.27M
Operating Income -20,221,333 -21,451,311 -18,634,068
Net Income -20,699,385 -25,319,011 -23,908,785
Gross Margin 59.2% 59.2% 59.2%
Operating Margin -23.9% -24.9% -24.3%
Profit Margin -24.5% -29.4% -31.2%
Rev Growth +3.2% +20.0% +0.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 97.43M 108.81M 97.98M
Total Equity 167.70M 160.32M 155.36M
D/E Ratio 0.58 0.68 0.63
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -24,990,141 -25,196,528 -24,930,968
Free Cash Flow -20,292,095 -20,848,476 -17,728,438